Xenetic Biosciences, Inc. 8-K

What Happened

• Xenetic Biosciences, Inc. announced its financial results for the three months ended March 31, 2026 in a press release dated May 13, 2026. The company filed a Current Report on Form 8-K (Item 2.02) to furnish that press release.
• The full press release is included as Exhibit 99.1 to the Form 8-K; the filing also includes the Inline XBRL cover page (Exhibit 104).

Key Details

• Filing date: May 13, 2026 (Form 8-K reporting results under Item 2.02).
• Reporting period: three months ended March 31, 2026 (Q1 2026).
• Exhibit furnished: 99.1 — Press Release dated May 13, 2026 detailing the company’s quarterly results.
• Technical filing item: 104 — Cover Page Interactive Data File (Inline XBRL).

Why It Matters

• This is the company’s formal disclosure of its quarterly earnings and financial condition for Q1 2026; investors should review the press release and the company’s published financial statements for revenue, profit/loss, cash position and any commentary on operations or outlook.
• The 8-K indicates the results have been publicly released; because the Form 8-K itself does not include numeric details in this filing text, retail investors should read Exhibit 99.1 (the press release) and any subsequent filings for the complete financial figures and management discussion.

Keywords: earnings, quarterly results, revenue, financial results, Form 8-K, Xenetic Biosciences.